Drug reference
palbociclib
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Drug class
Oncology (Anti Neoplastics)
Mechanism of action
Cyclin dependent kinases (CDK) 4,6 inhibitor. Reduces cellular proliferation of ER-positive breast cancer cell lines by blocking progression of the cell from G1 into S phase of the cell cycle
Common side effects
- Neutropenia
- Leukopenia
- Infections
- WBC decreased
- AST/ALT increased
- Neutrophils decreased
- Platelets decreased
Related conditions
Frequently asked questions
What drug class is palbociclib?
palbociclib belongs to: Oncology.
How does palbociclib work?
Cyclin dependent kinases (CDK) 4,6 inhibitor. Reduces cellular proliferation of ER-positive breast cancer cell lines by blocking progression of the cell from G1 into S phase of the cell cycle
What are the common side effects of palbociclib?
Neutropenia, Leukopenia, Infections, WBC decreased, AST/ALT increased, Neutrophils decreased, Platelets decreased
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.